

Cancer Drugs Tislelizumab and Zanubrutinib

Source: TH

India is set to get access to two new cancer drugs named Tislelizumab and Zanubrutinib.


- Tislelizumab, a new immunotherapy drug, is showing effectiveness in treating advanced oesophagal squamous cell carcinoma (Cancer that forms in the thin, flat cells lining the inside of the oesophagus).
- Zanubrutinib is a type of medication that inhibits a protein called Bruton's tyrosine kinase (BTK), which is important for the growth and survival of certain cancerous blood cells.
 - It has been approved for the treatment of specific types of blood cancers.
- <u>Cancer</u> refers to a group of diseases characterised by the <u>uncontrolled proliferation and</u> spread of abnormal cells in the body, which can infiltrate and harm healthy tissues and organs.
- In 2019, India had 1.2 million new cancer cases and 930,000 deaths, making it the second-highest contributor to the disease burden in Asia for that year.
 - The cancer cases in the country are projected to increase from 14.6 lakh in 2022 to 15.7 lakh in 2025, as per the <u>Indian Council of Medical Research</u>.







Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly 1 in 6 deaths.



- Cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low-and lower-middle-income countries.
- Many cancers can be cured if detected early and treated effectively.

Read more...

PDF Refernece URL: https://www.drishtiias.com/printpdf/cancer-drugs-tislelizumab-and-zanubrutinib